Care of the Cancer Survivor: Metabolic Syndrome after Hormone-Modifying Therapy

American Journal of Medicine

Volumn 123, Issue 1, 2010, Pages

  Redig, Amanda J ^a   Munshi, Hidayatullah G ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Androgen suppression therapy; Anti estrogen therapy; Breast cancer; Metabolic syndrome; Prostate cancer

Indexed keywords

ANDROGEN; ANTIANDROGEN; ANTIESTROGEN; AROMATASE INHIBITOR; GONADORELIN DERIVATIVE; LEUPRORELIN; TAMOXIFEN;

ABDOMINAL OBESITY; ANDROGEN DEPRIVATION THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FUNCTION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OVARIECTOMY; PHYSICIAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; SUDDEN DEATH;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; MONITORING, PHYSIOLOGIC; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVORS; TIME FACTORS;

EID: 72649099139     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.06.022     Document Type: Review

References (65)

1. Joslin E. The prevention of diabetes mellitus. JAMA 76 (1921) 79-84
2. Reaven G.M. Banting Lecture 1988. Role of insulin resistance in human disease. 1988. Nutrition 13 (1997) 65 discussion 64, 66
3. Fraze E., Donner C.C., Swislocki A.L., et al. Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab 61 (1985) 807-811
4. Ferrannini E., Natali A., Cerri M., et al. Hypertension: a metabolic disorder?. Diabetes Metab 15 (1989) 284-291
5. Foster D.W. Insulin resistance-a secret killer?. N Engl J Med 320 (1989) 733-734
6. Haller H. [Epidermiology and associated risk factors of hyperlipoproteinemia]. Z Gesamte Inn Med 32 (1977) 124-128
7. Pagano G., and Cassader M. Insulin resistance in spontaneous obesity. Role of insulin receptors. Minerva Dietol Gastroenterol 25 (1979) 265-274
8. Karam J.H. Type II diabetes and syndrome X. Pathogenesis and glycemic management. Endocrinol Metab Clin North Am 21 (1992) 329-350
9. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
10. Park Y.W., Zhu S., Palaniappan L., et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163 (2003) 427-436
11. Pothiwala P., Jain S.K., and Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord 7 (2009) 279-288
12. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
13. Cuppone F., Bria E., Verma S., et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer?. Meta-analysis of randomized trials. Cancer 112 (2008) 260-267
14. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
15. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
16. Solymoss B.C., Bourassa M.G., Marcil M., et al. Long-term rates of cardiovascular events in patients with the metabolic syndrome according to severity of coronary-angiographic alterations. Coron Artery Dis 20 (2009) 1-8
17. Boppidi H., and Daram S.R. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. Postgrad Med 120 (2008) E01-E07
18. Castaneda E., Perez A.E., Guillen M.A., et al. Metabolic studies in a patient with testicular feminization syndrome. Am J Obstet Gynecol 110 (1971) 1002-1007
19. Wortsman J., and Soler N.G. Abnormalities of fuel metabolism in the polycystic ovary syndrome. Obstet Gynecol 60 (1982) 342-345
20. Cupisti S., Kajaia N., Dittrich R., et al. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol 158 (2008) 711-719
21. Regitz-Zagrosek V., Lehmkuhl E., and Weickert M.O. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 95 (2006) 136-147
22. Dunaif A., and Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 52 (2001) 401-419
23. Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril 86 suppl 1 (2006) S13-S14
24. Stanworth R.D., and Jones T.H. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res 37 (2009) 74-90
25. Lunenfeld B. Testosterone deficiency and the metabolic syndrome. Aging Male 10 (2007) 53-56
26. D'Amico A.V., Renshaw A.A., Loffredo B., and Chen M.H. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 110 (2007) 1723-1728
27. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
28. Tsai H.K., D'Amico A.V., Sadetsky N., et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99 (2007) 1516-1524
29. Saigal C.S., Gore J.L., Krupski T.L., et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 (2007) 1493-1500
30. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24 (2006) 3979-3983
31. Traish A.M., Saad F., Feeley R.J., and Guay A.T. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 30 (2009) 477-494 Epub 2009 Apr 2
32. Lage M.J., Barber B.L., and Markus R.A. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70 (2007) 1104-1108
33. Basaria S., Muller D.C., Carducci M.A., et al. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106 (2006) 581-588
34. Traish A.M., Saad F., and Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 30 (2009) 23-32
35. Smith M.R., Lee H., Fallon M.A., and Nathan D.M. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 71 (2008) 318-322
36. Derweesh I.H., Diblasio C.J., Kincade M.C., et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 100 (2007) 1060-1065
37. Vuppalanchi R., and Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49 (2009) 306-317
38. Gabbi C., Carubbi F., Losi L., et al. Nonalcoholic fatty liver disease induced by leuprorelin acetate. J Clin Gastroenterol 42 (2008) 107-110
39. Herrington D.M., and Klein K.P. Cardiovascular trials of estrogen replacement therapy. Ann N Y Acad Sci 949 (2001) 153-162
40. Love R.R., Wiebe D.A., Newcomb P.A., et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115 (1991) 860-864
41. Dewar J.A., Horobin J.M., Preece P.E., et al. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ 305 (1992) 225-226
42. Saarto T., Blomqvist C., Ehnholm C., et al. Effects of chemotherapy-induced castration on serum lipids and apoproteins in premenopausal women with node-positive breast cancer. J Clin Endocrinol Metab 81 (1996) 4453-4457
43. McDonald C.C., Alexander F.E., Whyte B.W., et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ 311 (1995) 977-980
44. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
45. Buzdar A., Howell A., Cuzick J., et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 (2006) 633-643
46. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
47. Mouridsen H., Keshaviah A., Coates A.S., et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 25 (2007) 5715-5722
48. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
49. Rock C.L., Flatt S.W., Newman V., et al. Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group. J Am Diet Assoc 99 (1999) 1212-1221
50. Irwin M.L., Crumley D., McTiernan A., et al. Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer 97 (2003) 1746-1757
51. Chlebowski R.T., Aiello E., and McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 20 (2002) 1128-1143
52. Ahmed M.H., Saad R.A., and Osman M.M. Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother 6 (2005) 131-139 Expert Opin Drug Saf. 2006;5:487-488
53. Nguyen M.C., Stewart R.B., Banerji M.A., et al. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord 25 (2001) 296-298
54. Bruno S., Maisonneuve P., Castellana P., et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 330 (2005) 932
55. Dorum A., Tonstad S., Liavaag A.H., et al. Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecol Oncol 109 (2008) 377-383
56. Michelsen T.M., Pripp A.H., Tonstad S., et al. Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. Eur J Cancer 45 (2009) 82-89
57. Cuzick J., Ambroisine L., Davidson N., et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369 (2007) 1711-1723
58. Cohen P. Metformin for the prevention of androgen deprivation induced metabolic syndrome, obesity and type 2 diabetes. Med Hypotheses 72 (2009) 227-228
59. Goodwin P.J. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions?. J Clin Oncol 26 (2008) 833-834
60. Hede K. Doctors seek to prevent breast cancer recurrence by lowering insulin levels. J Natl Cancer Inst 100 (2008) 530-532
61. Mathur R., Alexander C.J., Yano J., et al. Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol 199 (2008) 596-609
62. Galvao D.A., Newton R.U., Taaffe D.R., and Spry N. Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT?. Nat Clin Pract Urol 5 (2008) 306-307
63. Martin C.K., Church T.S., Thompson A.M., et al. Exercise dose and quality of life: a randomized controlled trial. Arch Intern Med 169 (2009) 269-278
64. Ligibel J.A., Campbell N., Partridge A., et al. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol 26 (2008) 907-912
65. D'Amico A.V., Denham J.W., Bolla M., et al. Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate. Cancer 109 (2007) 2004-2010